Using information from a patient's entire genome helped suggest
personalized treatment options for nearly half of children with cancer,
and led to specific treatment changes in a quarter of these patients,
according to researchers at the University of Michigan Comprehensive
Cancer Center and C.S. Mott Children's Hospital.
The study is based on a program implemented at Mott in 2012 called
Peds-MiOncoSeq, which includes sequencing the tumor's DNA and RNA as
well as normal DNA from children and young adults with cancer that has
relapsed or that is rare. Results from the first 102 patients enrolled
are published in the Journal of the American Medical Association.
"We found that for some children with rare, difficult-to-treat and
aggressive cancers, this technology can dramatically change the course
of their treatment," says lead author Rajen Mody, M.D., M.S., pediatric
oncologist at U-M's C.S. Mott Children's Hospital.
"We have made significant strides in cancer treatment but for some
kids, especially those with metastatic or relapsed disease, even the
most advanced, proven therapies have not been able to improve their
outcome. Our approach in precision oncology showed its greatest promise
in these difficult to treat patients, 80 % of our study patients
had relapsed or refractory disease, and those are the ones who benefited
most from our study."
No comments:
Post a Comment